Lyell Immunopharma, Inc. · NASDAQ:LYEL
ARCH Venture Fund IX, L.P. reported a 13.00% stake in Lyell Immunopharma, Inc. (Schedule 13G/A)
Event Sep 30, 2025 · Filed Nov 14, 2025
ARCH Venture Fund IX, L.P. reported a 13.00% stake in Lyell Immunopharma, Inc., 2,759,072 shares, as a passive investor on Sep 30, 2025. Filed Nov 14, 2025 (Schedule 13G/A).
- Stake
- 13.00%
- Shares
- 2,759,072
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 14 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| ARCH Venture Fund IX, L.P. | 13.00% | 2,759,072 |
| ARCH Venture Fund IX Overage, L.P. | 13.00% | 2,759,072 |
| ARCH Venture Fund XIII, L.P. | 13.00% | 2,759,072 |
| ARCH Venture Partners IX, L.P. | 13.00% | 2,759,072 |
| ARCH Venture Partners IX Overage, L.P. | 13.00% | 2,759,072 |
| ARCH Venture Partners IX, LLC | 13.00% | 2,759,072 |
| ARCH Venture Partners XIII, L.P. | 13.00% | 2,759,072 |
| ARCH Venture Partners XIII, LLC | 13.00% | 2,759,072 |
| Keith Crandell | 13.00% | 2,759,072 |
| Clinton Bybee | 8.60% | 1,820,634 |
| Robert Nelsen | 13.00% | 2,759,072 |
| Kristina Burow | 13.00% | 2,759,072 |
| Steven Gillis | 13.00% | 2,759,072 |
| Paul Berns | 4.40% | 938,438 |
Source
Related
- Lyell Immunopharma, Inc.
- Robert Nelsen
- Lyell Immunopharma, Inc. shareholders
- Schedule 13G/A · Robert Nelsen · May 15, 2026
- Form 4 · Aguirre Jarrad Mattieu · Oct 13, 2026
- Form 4 · Shook David · Sep 10, 2026
- Form 4 · Seely Lynn · Aug 25, 2026
- Form 4 · Hill Stephen J. · Aug 25, 2026
- Form 4 · Lee Gary K. · Aug 25, 2026